Sarepta Therapeutics

Valuation Analysis

About the Company

Sarepta Therapeutics en bref

Sarepta Therapeutics (SRPT) is currently trading at 12,88 € with a market capitalization of 1,4 Md €. The trailing P/E ratio stands at 42.46x, with a forward P/E of 6.07x. The 52-week range spans from 12,73 € to 21,95 €; the current price is 41.3% below the yearly high. Year-over-year revenue growth stands at -1.9%. The net profit margin stands at 2.98%.

💰 Dividende

Sarepta Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

23 analystes évaluent Sarepta Therapeutics (SRPT) au consensus : Conserver. L'objectif de cours moyen est de 19,22 €, soit un potentiel de +49.22% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 4,34 € à 32,95 €.

Sarepta Therapeutics : la thèse d'investissement en détail

Sarepta Therapeutics (SRPT) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue is contracting at -1.9% year-over-year — until that trend reverses, valuation is exposed to further downgrades. With a net margin of just 2.98%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Short interest sits at 32.35% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The EV/EBITDA multiple of 42.5x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 6.07x is meaningfully below the trailing 42.46x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 49.22% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (32.35%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Sarepta Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.